Chang M-L, Vitek C, Esparza J
AIDS. 2003 Oct 17;17(15):W1-10. doi: 10.1097/01.aids.0000076356.20434.a0.
To accelerate the development and future availability of safe, effective and affordable HIV vaccines it is essential to address not only the associated biomedical obstacles, but also the logistic aspects that would guide the introduction and use of those vaccines. It is likely that initial vaccines may only be partially effective, and their public health use will have to be carefully considered. This report summarizes the discussions from a consultation held in Geneva (20-21 November 2002) organized by the World Health Organization (WHO), the joint United Nations Programme on HIV/AIDS (UNAIDS) and the US Centers for Disease Control and Prevention (CDC). The group identified a number of logistic issues that need to be addressed to accelerate the development and future availability of HIV vaccines, and made broad recommendations in four different areas: (a) Vaccine manufacturing and licensing; (b) vaccination acceptability and social marketing; (c) immunisation strategies and delivery; and (d) access and economic issues. The implementation of these recommendations will require the participation of multiple stakeholders in the public and private sector, in industrialized and developing countries. These actions will be essential to ensure widespread and rapid access to HIV vaccines globally, soon after their efficacy is demonstrated in clinical trials.
为加速安全、有效且可负担的HIV疫苗的研发及未来可得性，不仅要解决相关的生物医学障碍，还必须应对指导这些疫苗引进和使用的后勤方面问题。最初的疫苗可能仅部分有效，其在公共卫生方面的使用必须谨慎考虑。本报告总结了由世界卫生组织（WHO）、联合国艾滋病联合规划署（UNAIDS）和美国疾病控制与预防中心（CDC）于2002年11月20日至21日在日内瓦组织的一次磋商会的讨论内容。该小组确定了一些为加速HIV疫苗的研发及未来可得性而需解决的后勤问题，并在四个不同领域提出了广泛建议：（a）疫苗生产与许可；（b）疫苗可接受性与社会营销；（c）免疫策略与接种；以及（d）可及性与经济问题。这些建议的实施将需要公共和私营部门、工业化国家和发展中国家的多个利益相关者参与。这些行动对于确保在临床试验证明疫苗有效性后不久，全球范围内能广泛且迅速地获取HIV疫苗至关重要。
